Ontology highlight
ABSTRACT:
SUBMITTER: Cassinello J
PROVIDER: S-EPMC5785604 | biostudies-literature | 2018 Jan
REPOSITORIES: biostudies-literature
Cassinello J J Arranz J Á JÁ Piulats J M JM Sánchez A A Pérez-Valderrama B B Mellado B B Climent M Á MÁ Olmos D D Carles J J Lázaro M M
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20171113 1
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. Th ...[more]